"MAVENCLAD is indicated for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability.
Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4.
Re-initiation of therapy after year 4 has not been studied."
Each tablet of MAVENCLAD contains 10mg cladribine in a Pack of 1 Tab, 4 Tabs, 6 Tabs.
"The recommended cumulative dose of MAVENCLAD is 3.5mg/kg body weight over 2years, administered as 1treatment course of 1.75mg/kg per year. Each treatment course consists of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
Each treatment week consists of 4 or 5days on which a patient receives 10 mg or 20 mg (one or two tablets) as a single daily dose, depending on body weight.
Patients should receive no more than 2treatment courses over two consecutive years. The recommended dose should not be exceeded. Following completion of the 2treatment courses, no further cladribine treatment is required in year3 and year4 (refer to CLINICAL TRIALS).
Re-initiation of therapy after year 4 has not been studied."
Relapsing-Remitting Multiple Sclerosis (RRMS)
